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Abstract
Objective—To compare rates of preterm birth before 35 weeks based on cervical length
measurement at 16-20 weeks in women with twin gestations who received 17 alpha
hydroxyprogesterone caproate (17OHPC) or placebo.
Methods—This is a secondary analysis of a randomized, double-blind, placebo-controlled trial of
twin gestations exposed to 17OHPC or placebo. Baseline transvaginal ultrasound evaluation of
cervical length was performed prior to treatment assignment at 16-20 weeks. Cervical length
measurements were categorized according to the 10th, 25th, 50th and 75th percentiles in the women
studied. The effect of 17OHPC administration in women with a short (25th percentile) and long
(75th percentile) cervix was evaluated.
Results—Of 661 twin gestations studied, 221 (33.4%) women enrolled at 11 centers underwent
cervical length measurement. The 10th, 25th, 50th, 75th percentiles for cervical length at 16-20
weeks were 32, 36, 40 and 44 mm, respectively. The risk of preterm birth < 35 weeks was
increased in women with a cervical length < 25th percentile (55.8 vs. 36.9%, p=0.02). However, a
cervical length >75th percentile at this gestational age interval was not protective for preterm birth
(36.5 vs. 42.9%, p=0.42). Administration of 17OHPC did not reduce preterm birth before 35
weeks among those with either a short or a long cervix (64.3 vs. 45.8%, p=0.18 and 38.1 vs.
35.5%, p= 0.85, respectively).
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Conclusion—Women with twin gestations and a cervical length below the 25th percentile at
16-20 weeks had higher rates of preterm birth. In this subgroup of women, 17 OHPC did not
prevent preterm birth before 35 weeks gestation. A cervical length above the 75th percentile at
16-20 weeks did not significantly reduce the risk of preterm birth in this high risk population.
Introduction
Sonographic measurement of the cervix has been used to identify women with twin
gestations at increased risk for preterm birth1,2. Goldenberg et al. evaluated 147 twin
pregnancies at 24 and 28 weeks gestation showing that a cervical length of ≤ 25 mm at 24
weeks was associated with an increased risk of preterm birth before 32, 35 and 37 weeks
gestation1. In that study, 17.7% of the women with a twin pregnancy had a short cervix at 24
weeks compared with only 9.1% of women with singletons, suggesting that cervical
shortening occurs earlier in multiple gestations. Furthermore, Guzman et al. showed that
50% of twin gestations with a cervical length < 20 mm identified at 15-24 weeks gestation
delivered before 32 weeks3. Interventions such as cervical cerclage placement for short
cervix4,5 and home uterine activity monitoring6 have not decreased the rate of preterm birth
in twin gestations.
In women with a singleton gestation and a history of prior spontaneous preterm birth,
weekly injections of 17 alpha hydroxyprogesterone caproate (17OHPC) have been shown to
reduce the risk of recurrent preterm delivery7. Although the exact mechanism of how 17
OHPC works in the prevention of recurrent preterm birth is uncertain, there is evidence that
its anti-inflammatory properties may blunt inflammation mediated parturition8,9. These
findings led to studies of progesterone supplementation in other populations at risk for
spontaneous preterm birth such as women with a short cervix and those with multiple
gestations. Fonseca reported that weekly vaginal progesterone reduced the rate of preterm
birth in women with a short cervix < 15 mm (identified at 20-25 weeks gestation) without
regard to risk factors10. Although this study enrolled 25 women with twin gestations, the
number was too small to allow specific assessment of the effect of 17 OHPC on twin
gestations.
A recent randomized trial found no reduction in the rate of preterm delivery in women with
twin gestations receiving weekly 17 OHPC compared with placebo11. The mechanism of
preterm birth in multiple gestations may be related to uterine distention suggesting that it
would be unaffected by 17OHPC. However, there may be a subset of women with a twin
gestation identified to have early second trimester cervical shortening in which there is an
inflammation-mediated component to preterm parturition. Therefore, we sought to evaluate
the rates of preterm birth before 35 weeks gestation in women with a twin gestation who
received 17OHPC compared with placebo based on their cervical length measurement at
16-20 weeks.
Materials and Methods
This study is a secondary analysis of the Maternal Fetal Medicine Units Network (MFMU)
STTARS trial, which was a 2 year (April 2004 to February 2006) placebo controlled, double
blind, randomized clinical trial conducted at 14 academic medical centers designed to
evaluate whether 17 OHPC was effective in the prevention of preterm birth in twin
gestations. Each center’s institutional review board approved the study protocol. The study
protocol has been previously described11. Maternal and neonatal outcomes of this
population have been reported in a previous publication11.
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This analysis includes data from women with twin gestations who underwent transvaginal
ultrasound evaluation of cervical length at 16 – 20 weeks gestation prior to randomization to
treatment assignment. Cervical length measurement was not required by the study protocol,
and was performed at the discretion of the obstetrical care providers. If obtained,
endovaginal sonography was used to measure cervical length in a standardized fashion as
previously reported1.
Pregnancies in which the viability of any of the fetuses was in question on the last US before
randomization, monoamniotic twin gestation, suspected twin to twin transfusion syndrome,
ultrasonographic growth discordance greater than 3 weeks, planned non-study progesterone
therapy after 16 weeks, in place or planned cerclage, major uterine anomaly, selective fetal
reduction, anticoagulation therapy and chronic medical illness such as insulin dependent
diabetes mellitus and pharmacologically treated chronic hypertension were not randomized
into the STTARS trial.
Cervical length measurements were analyzed to determine the 10th, 25th, 50th and 75th
percentiles in the women studied. The number of women with cervical length measurements
below the 10th percentile was inadequate to allow statistical analysis. The 25th percentile
was therefore chosen as a threshold for a short cervix. Women with a short cervical length
defined as below the 25th percentile were compared with women with a cervical length at or
above the 25th percentile to determine whether differences existed in rates of preterm birth.
In addition, women with a cervical length above the 75th percentile were compared with
those whose cervical length measurement was at or below the 75th percentile to determine
whether there was a reduction in the rate of preterm birth with a longer cervix. Maternal
clinical characteristics and delivery outcomes were recorded. Preterm birth was defined as
delivery or fetal death before the 35th completed week of gestation as this was the endpoint
in the primary trial. These groups were subsequently analyzed to determine if 17OHPC
exposure altered the risk of preterm birth.
Statistical analysis was conducted with SAS software (SAS Institute, Cary, NC). Continuous
variables were compared with the Wilcoxon rank sum test. Categorical variables were
analyzed by using the Chi square or Fisher’s exact test, where appropriate. Stratified
analyses were performed to evaluate the possible effect of 17 OHPC exposure on the rate of
preterm birth in those women identified to have a short cervix and a long cervix. A nominal
p value of <0.05 was considered significant and no adjustments were made for multiple
comparisons.
Results
Of the 661 women with twin gestations in the original trial, 221 (33.4%) underwent baseline
transvaginal cervical length assessment prior to treatment assignment. These 221 women
were enrolled at 11 centers (86% from 5 institutions) and represent 39.3% of the women
enrolled at those sites. There was no difference in rates of preterm birth before 35 weeks
gestation in women who underwent cervical sonography during the study period compared
with those with no cervical assessment (41.4 vs. 38.4%, p=0.46). Clinical and pregnancy
characteristics of women who underwent cervical length assessment and those who did not
were similar except that women who had a cervical length measurement were older (Table
1). Mean cervical length of the study population at 16-20 weeks gestation was 40.1 ± 7.3
mm (range 16-72). The 10th, 25th and 75th percentiles were 32, 36 and 44 mm. There were
20 women with a cervical length < 10th percentile. Twelve (60%) of women with a cervical
length less than the 10th percentile delivered before 35 weeks gestation.
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There were 52 women (24%) with a cervical length below the 25th percentile. One patient in
the cervical length ≥ 25th percentile group was lost to follow up. Clinical and pregnancy
characteristics of women with a cervix < 25th percentile and greater than or equal to the 25th
percentile are shown in Table 2. Women with a short cervix were younger than those with a
cervical length above the 25th percentile. Race, gravidity, parity, pregravid body mass index
(BMI), history of prior preterm birth, chorionicity and conception by assisted reproductive
technology were similar between groups. There was no difference in the gestational age at
randomization between women with a short cervix and those with a cervical length at or
above the 25th percentile (19.5 ± 1.4 vs. 19.4 ± 1.4 weeks, p=0.54).
The rate of preterm birth before 35 weeks gestation was significantly greater in women with
a cervical length below the 25th percentile compared with those with a cervical length at or
above the 25th percentile, 55.8% vs. 36.9%, p=0.02. In the subset of women with a short
cervix, the rate of preterm birth before 35 weeks was similar in the 17 OHPC and placebo
groups (Table 3).
Fifty three women (32.1%) had a cervical length measurement above the 75th percentile.
Clinical characteristics of women with a cervix greater 75th percentile and less or equal to
the 75th percentile were similar (Table IV). The rate of preterm delivery was not lower in
women with a cervical length above the 75th percentile compared with those with a cervical
measurement at or below the 75th percentile (36.5 vs. 42.9%, p=0.42). The rate of preterm
birth < 35 weeks was similar in those women with a long cervix receiving 17OHPC and
placebo as shown in Table V. When excluding the 20 women with a cervical length ≥
50mm, rates of preterm birth remained similar in both the 17 OHPC and placebo groups
(41.5 and 44.7%, respectively).
Discussion
In our analysis, we have shown that treatment with 17OHPC did not reduce the rate of
preterm delivery before 35 weeks in women with a short cervix and a twin gestation. In a
smaller study, Fonseca found that vaginal progesterone administration was not associated
with significant reduction in preterm birth in 24 women with a twin gestation whose cervical
length was 15 mm or less10.
We found higher rates of preterm delivery before 35 weeks in the women with a cervical
length below the 25th percentile compared with those with a cervical length above the 25th
percentile. This agrees with previous studies evaluating twin gestations showing that a short
cervix in the mid trimester of pregnancy is associated with a high risk of preterm birth2,3.
It is plausible that we were not able to detect a beneficial effect for progesterone therapy in
women with twins because of the combination of risk factors present: multiple gestation and
a short cervix. A short cervix has been shown to be a stronger predictor of preterm birth than
obstetrical history alone in singletons12-14. Furthermore, the relationship between a short
cervix and preterm birth in multiple gestations is well known1-3. Therefore, these two risk
factors for preterm birth may be additive and confer such an increased risk for preterm birth
that cannot be overcome by administration of 17 OHPC. The route of administration and the
formulation of progesterone used in our trial differ from the progesterone used in other
studies that have documented a treatment response for premature cervical shortening.
Thereby, the ability of differing progestins to alter outcomes for specific indications may
vary.
In a previous report by Imseis, a cervical length above 30 mm after 24 weeks was associated
with a lower rate of preterm birth15. Our study was unable to identify a similar threshold of
cervical length in the early second trimester at which the risk of preterm birth was reduced
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in twin gestations. Even those women with a cervical length above the 75th percentile
corresponding to 44 mm had a preterm delivery rate of 36%. Therefore, a long cervix at
16-20 weeks may not provide useful clinical information to the obstetrician regarding risk of
preterm delivery in twin gestations. Furthermore, a long cervix is likely only reassuring if it
is maintained beyond 24 weeks gestation as demonstrated by Imseis15.
Although only 33.4% of women enrolled in the original trial underwent cervical length
assessment prior to treatment assignment, clinical characteristics of these women were
similar to those women in whom the cervix was not evaluated. Therefore, we believe that
the women included in our analysis were not screened based on risk factors but typically as
part of standard clinical practice at the institution where they received prenatal care and are
likely representative of the population as a whole.
Our findings, which do not support the initiation of progesterone therapy in women with a
twin gestation and a short cervix, are limited by the small number of women included in this
secondary analysis, and thus can only be interpreted as hypothesis generating. In order to
demonstrate a 50% reduction in the rate of preterm birth with 17OHPC therapy, with type I
error 0.05 and power 80%, we would need 74 women in each treatment arm. Furthermore,
we defined a short cervix as less than the 25th percentile instead of the more widely accepted
10th percentile, due to the small number of women in the latter group. However, the
measurement at the 10th percentile did not represent a substantially shorter cervix with a 4
mm difference between the two percentiles.
Given recent reports showing a reduction in the rate of preterm birth in progesterone treated
women with singleton pregnancies and early preterm birth16 and short cervix10,17, the
observations from this analysis are consistent with the hypothesis that cervical shortening in
multiple gestations is related to uterine overdistention and that this distention is not
progesterone sensitive.
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Table 1
Maternal and pregnancy characteristics of women based on whether cervical length assessment was performed
at 16-20 weeks
Cervical US performed (n=221) Cervical US not performed (n=440) P value
Maternal age* 30.6 ± 6.8 29.2 ± 6.9 0.02
African American (%) 51 (23.1) 104 (23.6) 0.87
Primigravida (%) 71 (32.1) 124 (28.2) 0.29
Primipara (%) 106 (48.0) 190 (43.2) 0.24
Prepregnancy BMI (kg/m2)* 26.6 ± 6.8 27.0 ± 6.8 0.50
Prior preterm birth** (%) 19 (16.5) 31 (12.4) 0.29
Monochorionicity (%) 29 (15.0) 62 (17.3) 0.49
Assisted reproductive technology (%) 57 (25.8) 99 (22.5) 0.35
*
Mean ± Standard deviation
**
Evaluated on a subset of multiparous women
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Table 2
Maternal and pregnancy characteristics of women based on cervical length
Cervix < 25th percentile (n=52) Cervix ≥ 25th percentile (n=169) P value
Maternal age* 29.0 ± 6.5 31.0 ± 6.8 0.046
African American (%) 16 (30.8) 35 (20.7) 0.13
Primigravida (%) 19 (36.5) 52 (30.8) 0.44
Primipara (%) 25 (48.1) 81 (47.9) 0.99
Prepregnancy BMI (kg/m2)* 27.5 ± 7.6 26.4 ± 6.5 0.59
Prior preterm birth** (%) 5 (18.5) 14 (15.9) 0.77
Monochorionicity (%) 8 (18.2) 21 (14.1) 0.48
Assisted reproductive technology (%) 10 (19.2) 47 (27.8) 0.22
*
Mean ± Standard deviation
**
Evaluated on a subset of multiparous women
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Table 3
Rate of preterm delivery before 35 weeks for women based on cervical length measurement
17 OHPC Placebo P-value
Cervix < 25th percentile 18/28 (64.3%) 11/24 (45.8%) 0.18
Cervix ≥ 25th percentile 25/73 (34.4%) 37/95 (39.0%)* 0.53
P-value 0.006 0.54
*
one patient lost to follow up
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Table 4
Maternal and pregnancy characteristics of women based on cervical length
Cervix > 75th percentile (n=53) Cervix ≤ 75th percentile (n=168) P value
Maternal age* 31.0 ± 6.9 30.4 ± 6.8 0.52
African American (%) 9 (17.0) 42 (25.0) 0.23
Primigravida (%) 39 (73.6) 111 (66.1) 0.31
Primipara (%) 32 (60.4) 83 (49.4) 0.16
Prepregnancy BMI (kg/m2)* 26.4 ± 7.1 26.7 ± 6.7 0.61
Prior preterm birth** (%) 30 (93.8) 66 (79.5) 0.09
Monochorionicity (%) 10 (22.2) 19 (12.8) 0.15
Assisted reproductive technology (%) 40 (75.5) 124 (73.8) 0.81
*
Mean ± Standard deviation
**
Evaluated on a subset of multiparous women
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Table 5
Rate of preterm delivery before 35 weeks for women based on cervical length measurement
17 OHPC Placebo P-value
Cervix > 75th percentile 8/21(38.1%) 11/31 (35.5%) 0.85
Cervix ≤ 75th percentile 35/80 (43.8%) 37/88 (42.1%)* 0.82
P-value 0.64 0.52
*
one patient lost to follow up
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